CIK: 0001560009 · Show all filings
Period: Q1 2021 (← Previous) (Next →)
Filing Date: May 7, 2021
Total Value ($000): $513,262 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | 1,554,960 | $189,472 | 36.9% | $40.26 | +275.0% | Common Shares | H17182108 |
| — | Passage Bio, Inc. | 4,959,769 | $86,697 | 16.9% | $17.48 | — | Common Stock | 702712100 |
| — | Aligos Therapeutics, Inc. | 3,292,339 | $74,868 | 14.6% | $27.65 | — | Common Stock | 01626L105 |
| — | Adverum Biotechnologies, Inc. | 5,068,233 | $49,973 | 9.7% | $9646.10 | — | Common Stock | 00773U108 |
| — | Gritstone Oncology, Inc. | 4,450,638 | $41,970 | 8.2% | $7767.86 | — | Common Stock | 39868T105 |
| CRNX | Crinetics Pharmaceuticals, Inc. | 2,030,616 | $31,028 | 6.0% | $17.05 | -9.1% | Common Stock | 22663K107 |
| — | Akero Therapeutics, Inc. | 617,727 | $17,920 | 3.5% | $21200.00 | — | Common Stock | 00973Y108 |
| — | Flexion Therapeutics, Inc. | 1,310,169 | $11,726 | 2.3% | $10.41 | — | Common Stock | 33938J106 |
| — | Aprea Therapeutics, Inc | 1,259,662 | $6,424 | 1.3% | $38780.00 | — | Common Stock | 03836J102 |
| — | CymaBay Therapeutics, Inc. | 543,753 | $2,469 | 0.5% | $9871.60 | — | Common Stock | 23257D103 |
| — | Clovis Oncology, Inc. | 101,855 | $715 | 0.1% | $56000.00 | — | Common Stock | 189464100 |